Publications

Topp MS, Shah BD, Jabbour E, Park JH, Shaughnessy P, Logan AC, Sandhu KS, Abedi M, Bishop MR, DeAngelo DJ, Yin X, Davi R, Hodby K, Malladi R, Brugger W, Shang J, Roddie C, Kantarjian HM. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42469475

Amouzegar A, Shaw R, Tsai KK, Olson D, Gibney GT. Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2026. PMID: 42462189

Ho LS, Alsultan A, Smits MLJ, Koopman M, Bruijnen R, Braat AJAT, Fowers KD, Dreher MR, Bol GM, Lam MGEH. Phase I Dose-Escalation Study Combining Irinotecan-Loaded Drug-Eluting Bead Chemoembolization with Yttrium-90 Glass Microspheres Radioembolization in Colorectal Liver Metastases (DEBIR90Y). Journal of vascular and interventional radiology : JVIR. 2026. PMID: 42462844

Cho B, Usman L, Lomax Truong T, Phelan D, Datta D, Aras MA, Hetts S, Ohliger M, Conrad M, Ge J. Incidence and diagnostic yield of repeat imaging-based screening for hepatic arteriovenous malformations in patients with HHT. Hepatology communications. 2026. PMID: 42486800

Li C, Venkatesh H, Trieu L, Fong L. Strategic engineering B cell immunity for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society. 2026. PMID: 42456977

Moore CG, Chyong DI, Daver N, Aubrey BJ, Marx KR, Takahashi K, Abaza Y, Smith CC, Amrein PC, Hock H, Hobbs G, Narayan R, Lee MH, Moran JA, Bergeron M, Foster JE, Perl AE, Levis MJ, DiNardo CD, Brunner AM, Fathi AT. Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. British journal of haematology. 2026. PMID: 42438311

Keane G, Lam MGEH, Smits MLJ, Bol GM, de Jong HWAM, Bruijnen RCG, Braat AJAT. A novel approach to radioembolization treatment planning using a hybrid [99mTc]Tc-MAA contrast enhanced SPECT/CT. European journal of nuclear medicine and molecular imaging. 2026. PMID: 42435201

Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Cardio-oncology (London, England). 2026. PMID: 42432812

Kamran SC, Borges M, Michalski J, Lee WR, Sandler HM, Crook J, Pollack A, Hurwitz MD, Valicenti RK, Bruner DW, Lukka H, Jones CU, Roach M, Lawton C, Rosenthal SA, Pisansky TM, Spratt D, Vapiwala N, Efstathiou J, Miyamoto D, Mouw K, Vyfhuis M, Le QT, Willers H, Van Allen E, Huang F, Bahary JP, Helou J, Pugh SL, Wenzel J, Tran P. Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology. JCO precision oncology. 2026. PMID: 42418740

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan X, Bamias A. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treat ESMO open. 2026. PMID: 42418909

Schroers-Martin JG, Merryman R, Spinner MA, Yeung A, Chang C, Silin C, Powell M, Armand P, Shipp M, Advani R. Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma. Haematologica. 2026. PMID: 42389806

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E, PRISM-AML Investigators. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 42391582

Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. American journal of hematology. 2026. PMID: 42393840

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Leitch AM, Lyons J, McCloskey S, McShane M, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Speers C, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42425164

Roddie C, Day W, Raymond M, Cluxton D, Caulfield J, Dainton-Smith H, McElwee B, Hu Y, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Yallop D, Barba P, Guerreiro M, Yared JA, Hodby K, Shah BD, Brugger W, Lao-Sirieix P, Bishop MR, DeAngelo DJ, Jabbour E, Park JH. CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Research Communications. 2026. PMID: 42241689

Piawah S, Lin OM, Mendiola DM, Yom SS, Macaire G, Cheng SW, Atreya CE. Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers. Seminars in radiation oncology. 2026. PMID: 42288373

Hotca AE, Lin OM, Piawah S, Mendiola DM, Yom SS, Kuon C, Atreya CE. The Role of the Microbiome and Gut Health in Patients With Digestive Tract Cancers. Seminars in radiation oncology. 2026. PMID: 42288363

Reyes KR, Zhu R, Herberts C, Dutta P, Wray A, Mitchell B, Balkhi SS, Zhu X, Chu CE, Porten SP, Friedlander TW, Chou J, Seyedin SN, Sharma S, Malhotra M, ElNaggar AC, Liu MC, Ayanambakkam A, Koshkin VS. Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab. European urology oncology. 2026. PMID: 42379901

Jones V, Wang Y, Quinones C, Aljaber D, Nelson E, Nath A, Kang I, Rugo H, Yee L, Seewaldt V, Mortimer J. Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort. Research square. 2026. PMID: 42427842

Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Cordoba Mascunano R, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. PMID: 42377594